Trump Administration Set to Reclassify Marijuana This Week
The Trump administration is expected to reclassify marijuana from Schedule I to Schedule III as soon as this week, easing research barriers after months of delay.
/ 1659 items
#XY↓
Amneal Acquires Kashiv BioSciences in $1.1B Deal to Ride $300 Billion Biosimilar Wave
Amneal is buying Kashiv BioSciences for up to $1.1 billion to become a global leader in affordable biosimilar drugs. Strong Q1 results beat expectations and 2026 guidance raised.
$8 Billion Opportunity: Inhibrx’s Experimental Cancer Drug Draws Major Interest
Inhibrx is drawing strong interest from Merck and other big pharma for its experimental cancer drug INBRX-106 that could boost Keytruda. Potential $9B spin-off value.
Kyverna’s miv-cel Scores Historic Win in Stiff Person Syndrome – First CAR-T Poised for FDA Approval
Kyverna’s CAR-T drug greatly improved rare SPS: patients walked 46% faster, many stopped meds; FDA filing planned 2026.
CVC and GTCR Team Up to Take Medical Device Maker Teleflex Private
Private equity firms CVC Capital Partners and GTCR have submitted a joint offer to take medical device company Teleflex (TFX) private. Shares jumped on the news.
Merck and Eisai Phase 3 Miss Shakes Up Kidney Cancer Race – Analysts Split on Arcus
Merck’s new kidney cancer combos failed in Phase 3, missing key goals; analysts see mixed impact for Arcus and its drug.